Introduction
ovarian cancer, platinum-sensitive recurrent cancer
OVARIAN CANCER, DISEASE
Patients with ovarian cancer who have received primary surgery followed by platinum-based chemotherapy will most likely experience disease recurrenceIn the platinum-sensitive recurrent cancer setting, maintenance with poly(ADP-ribose) polymerase (PARP) inhibitors was found to significantly improve progression-free survival (PFS) regardless of the To improve the outcomes for The aforementioned clinical studies, along with scientific research on the mechanisms